The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study.
E. L. Mayer
No relevant relationships to disclose
M. E. Scheulen
No relevant relationships to disclose
J. Beckman
No relevant relationships to disclose
H. Richly
No relevant relationships to disclose
A. Poli
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
P. Bhargava
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
A. Duarte
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. M. Cotreau
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
A. L. Strahs
Employment or Leadership Position - AVEO
Stock Ownership - AVEO
M. N. Dickler
No relevant relationships to disclose